CareDx (NASDAQ: CDNA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it contrast to its peers? We will compare CareDx to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, dividends, valuation, earnings and risk.

Volatility and Risk

CareDx has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, CareDx’s peers have a beta of 1.24, indicating that their average stock price is 24% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for CareDx and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx 0 0 4 0 3.00
CareDx Competitors 109 458 535 18 2.41

CareDx currently has a consensus price target of $8.88, indicating a potential downside of 3.53%. As a group, “Medical laboratories” companies have a potential upside of 17.50%. Given CareDx’s peers higher probable upside, analysts clearly believe CareDx has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares CareDx and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CareDx $48.32 million -$55.46 million -11.95
CareDx Competitors $1.13 billion $76.65 million 210.42

CareDx’s peers have higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares CareDx and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CareDx -114.79% -349.65% -22.88%
CareDx Competitors -118.64% -181.74% -42.76%

Institutional and Insider Ownership

51.5% of CareDx shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 5.4% of CareDx shares are held by company insiders. Comparatively, 18.4% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


CareDx peers beat CareDx on 7 of the 12 factors compared.

About CareDx

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with's FREE daily email newsletter.